Based on promising preclinical studies, our group conducted a Phase 1 clinical trial of 111In-DTPA-hEGF in 16 patients with metastatic EGFR-positive breast cancer administered 370–2220 MBq (0.25 mg) (Vallis et al. 2014) (Fig. 10). Here, EGFR is linked to breast carcinoma.